Condition: Medulloblastoma · Medulloblastoma, Childhood · Medulloblastoma Recurrent · Sponsor: University of California, San Francisco
The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in the pilot phase of performing real-time drug screening on tissue taken during surgery in patients with relapsed medulloblastoma or ependymoma and of having a specialized tumor board assign a treatment plan based on the results of this screening and genomic sequencing. The aim of this trial is to allow every child and young adult with relapsed medulloblastoma and ependymoma to receive the most effective and least toxic therapies currently available and will pave the way for improved understanding and treatment of these tumors in the future. Moreover, if successful, it could serve as a paradigm for personalized medicine programs for other types of cancer.
This description comes directly from the study's public registry record.
PNOC Operation Office · 415-502-1600 · PNOC027@ucsf.edu
Always discuss trial participation with your own doctor first.
| Children's Hospital of Los Angeles | Los Angeles, California, United States | Recruiting |
| Rady Children's Hospital | San Diego, California, United States | Recruiting |
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| Children's National Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| St. Louis Children's Hospital / Washington University in St. Louis | St Louis, Missouri, United States | Recruiting |
| New York University | New York, New York, United States | Recruiting |
| Columbia University Medical Center | New York, New York, United States | Recruiting |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05057702